UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/693,955	10/28/2003	Robert Naylor Laurie	P07351US01/BAS	3799
881 STITES & HAI	7590 06/30/201 RBISON PLLC	EXAMINER		
	FAIRFAX STREET	SHEIKH, HUMERA N		
ALEXANDRIA	A, VA 22314	ART UNIT	PAPER NUMBER	
			1615	
			MAIL DATE	DELIVERY MODE
			06/30/2010	PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

## Advisory Action Before the Filing of an Appeal Brief

Application No.	Applicant(s)	
10/693,955	LAURIE ET AL.	
Examiner	Art Unit	

	Humera N. Sheikh	1615	
The MAILING DATE of this communication appe	ars on the cover sheet with the o	correspondence add	ress
THE REPLY FILED <u>16 June 2010</u> FAILS TO PLACE THIS APP		-	
1. The reply was filed after a final rejection, but prior to or on application, applicant must timely file one of the following application in condition for allowance; (2) a Notice of Appelor Continued Examination (RCE) in compliance with 37 Coperiods:	the same day as filing a Notice of a replies: (1) an amendment, affidavi eal (with appeal fee) in compliance	Appeal. To avoid aban it, or other evidence, w with 37 CFR 41.31; or	hich places the (3) a Request
a) The period for reply expires <u>3</u> months from the mailing date	of the final rejection.		
b) The period for reply expires on: (1) the mailing date of this A no event, however, will the statutory period for reply expire la Examiner Note: If box 1 is checked, check either box (a) or (MONTHS OF THE FINAL REJECTION. See MPEP 706.07(f)	ater than SIX MONTHS from the mailing b). ONLY CHECK BOX (b) WHEN THE	g date of the final rejectio	n.
Extensions of time may be obtained under 37 CFR 1.136(a). The date of have been filed is the date for purposes of determining the period of extunder 37 CFR 1.17(a) is calculated from: (1) the expiration date of the set forth in (b) above, if checked. Any reply received by the Office later may reduce any earned patent term adjustment. See 37 CFR 1.704(b). NOTICE OF APPEAL	ension and the corresponding amount hortened statutory period for reply origi than three months after the mailing dat	of the fee. The appropriationally set in the final Office	ate extension fee e action; or (2) as
<ol> <li>The Notice of Appeal was filed on A brief in comp filing the Notice of Appeal (37 CFR 41.37(a)), or any exter Notice of Appeal has been filed, any reply must be filed with AMENDMENTS</li> </ol>	nsion thereof (37 CFR 41.37(e)), to	avoid dismissal of the	
3. The proposed amendment(s) filed after a final rejection, be	out prior to the date of filing a brief	will not be entered be	cause
(a) They raise new issues that would require further cor			cause
(b) They raise the issue of new matter (see NOTE below		,,	
(c) They are not deemed to place the application in bet	ter form for appeal by materially red	ducing or simplifying th	ne issues for
appeal; and/or (d) ☐ They present additional claims without canceling a c	corresponding number of finally reig	acted claims	
NOTE: (See 37 CFR 1.116 and 41.33(a)).	corresponding number of finally reje	scied ciaims.	
4. The amendments are not in compliance with 37 CFR 1.12	21 See attached Notice of Non-Co	mpliant Amendment (F	PTOL-324)
<ul><li>5. Applicant's reply has overcome the following rejection(s):</li></ul>		mphane / monamone (r	102 02 1).
6. Newly proposed or amended claim(s) would be all non-allowable claim(s).		timely filed amendmen	t canceling the
7. For purposes of appeal, the proposed amendment(s): a) how the new or amended claims would be rejected is proved the status of the claim(s) is (or will be) as follows:  Claim(s) allowed: 1,3,4,8,10,13 and 15.		l be entered and an ex	planation of
Claim(s) objected to: Claim(s) rejected: <u>11, 12 and 14</u> . Claim(s) withdrawn from consideration:			
AFFIDAVIT OR OTHER EVIDENCE			
<ol> <li>The affidavit or other evidence filed after a final action, but because applicant failed to provide a showing of good and was not earlier presented. See 37 CFR 1.116(e).</li> </ol>			
<ol> <li>The affidavit or other evidence filed after the date of filing entered because the affidavit or other evidence failed to o showing a good and sufficient reasons why it is necessary</li> </ol>	vercome <u>all</u> rejections under appea	al and/or appellant fails	s to provide a
10.	n of the status of the claims after e	ntry is below or attache	ed.
<ol> <li>The request for reconsideration has been considered but See Continuation Sheet.</li> </ol>	t does NOT place the application in	ı condition for allowand	ce because:
12.  ☐ Note the attached Information <i>Disclosure Statement</i> (s). ( 13.  ☐ Other:	PTO/SB/08) Paper No(s)		
	/Humera N. Sheikh/ Primary Examiner, Art U	Init 1615	

Continuation of 11. does NOT place the application in condition for allowance because:

Applicant argued, "Howard fails to provide an enabling disclosure for one of ordinary skill in the art to produce a trace element solution comprising a metal concentration of 60 mg/ml. Howard would not have allowed one of ordinary skill in the art to produce a trace element solution having a metal concentration of 60 mg/ml, let alone 72 mg/ml as alleged by the Examiner. All examples in Howard include a substantially smaller concentration than the 60 mg/ml."

Applicant's arguments have been considered but were not found persuasive. The disclosure of Howard is enabling for the production of a trace element solution having a possible 72 mg/ml total metal concentration, since Howard explicitly teaches and suggests suitable and effective ranges for each of the trace elements claimed. Applicant is arguing and emphasizing the preferred embodiments of Howard (at column 5, lines 40-59) and is disregarding the fact that Howard vividly discloses ranges of both low and high amounts of trace elements, whereby one of ordinary skill in the art would choose higher amounts of the trace elements, if so desired. The reference at column 5, lines 26-39, is clearly suggestive of effective ranges, whereby high amounts of the trace elements is taught and therefore, can be used. Moreover, Applicant is also arguing the lower amounts used in the Examples of Howard, namely, Examples 1 and 2. However, the Examiner points out that disclosed examples and preferred embodiments do not constitute a teaching away from a broader disclosure or nonpreferred embodiments. See In re Susi, 440 F.2d 442, 169 USPQ 423 (CCPA 1971). Furthermore, the teachings of the prior art are not limited to the examples disclosed therein.

Applicant argued, "Howard fails to be an anticipatory reference of claims 11, 12 and 14."

This was not persuasive. The Examiner reminds Applicant that the claims (11, 12, 14 and 16) have been rejected under 35 U.S.C. §103(a) and not under 35 U.S.C. §102. Thus, one of ordinary skill in the art would find the instant invention prima facie obvious, at the time the invention was made, based on the teachings of Howard. Howard explicitly teaches and suggests effective ranges for each of the trace elements claimed, including both low and high amounts of trace elements, which would read on the concentration levels as claimed (60 mg/ml).

Applicant argued, "The reason the Howard method would be insufficient for producing the higher concentrations required include the fact that Howard discloses a method of producing individual trace element solutions which are combined together to form a single trace element solution comprising all of its trace elements and thus discloses a batch method".

This argument was not persuasive. Note that the rejected claims are drawn to "product" claims and not process of making claims, nor product-by-process claims. As such, the process by which the product is formed does not impart patentable weight. The claims are merely drawn to an "injectable trace element solution", indicative of product claims. Moreover, Howard recognizes ranges of trace elements, whereby the upper limit claimed would read on the "60 mg/ml" claimed by Applicant.

Applicant argued, "Howard uses tetrasodium EDTA, whereas the present invention uses EDTA and/or disodium EDTA." This was not persuasive. Note that none of claims 11, 12 or 14 recite any reference to EDTA and/or disodium EDTA. The claims merely claim an "injectable trace element solution", with no mention of EDTA and/or disodium EDTA, as argued by Applicant. Hence, the tetrasodium EDTA of Howard is permissible, given the present claim language. Further, for the reasons advanced in the FInal Rejection (filed 3/16/10), Applicant's arguments were not deemed persuasive.